NEW HOPE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, Orchestra BioMed or the Company), a biomedical company accelerating high-impact technologies to...
Patent estate covering atrioventricular interval modulation (AVIM) therapy includes 37 issued U.S. patents and 73 patents outside the U.S. that collectively comprise over 1,800 claims related to the...
Initiated enrollment of the BACKBEAT global pivotal study evaluating AVIM therapy (also known as BackBeat Cardiac Neuromodulation Therapy) in hypertensive pacemaker patients in collaboration with...
Orchestra Announces Appointment of David to Board of Directors
Orchestra BioMed and Medtronic, Inc., have an exclusive strategic collaboration for development and commercialization of AVIM therapy for hypertensive pacemaker population, which is estimated to be...
NEW HOPE, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (œOrchestra BioMed or the œCompany), a biomedical company accelerating high-impact technologies to...
Hypertension is the most common comorbidity in the pacemaker population, affecting over 70% of patients or approximately 750,000 people annually worldwideMedtronic plc and Orchestra BioMed have an...
U.S. Food and Drug Administration (œFDA) granted Investigational Device Exemption (œIDE) approval with conditions for Virtue SAB® coronary in-stent restenosis (œISR) U.S. pivotal study (in...
Virtue® Sirolimus AngioInfusion Balloon (œSAB) is the only non-coated angioplasty system providing protected delivery of extended release sirolimus under clinical investigation worldwideVirtue ISR-US...
NEW HOPE, Pa., June 26, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, œOrchestra BioMed or the œCompany), a biomedical company accelerating high-impact technologies to...